Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H, Hiruma K, Matsunaga T, Morita T, Sakamaki H
Bone Marrow Transplantation Team, Tokyo Metropolitan Komagome Hospital, Japan.
Bone Marrow Transplant. 2000 Oct;26(8):881-6. doi: 10.1038/sj.bmt.1702624.
Hepatic veno-occlusive disease (VOD) is a major complication after hematopoietic stem cell transplantation (HSCT). Aetiological determinants, diagnosis and treatment remain unclear. Changes in coagulation-fibrinolysis parameters and N-terminal propeptide for type III procollagen (P-III-P) have been studied in patients with or without VOD after HSCT. We prospectively measured protein C activity, tissue plasminogen activator (t-PA), antithrombin III (AT-III), plasminogen activity (PLG), thrombin-antithrombin III (TAT), alpha2-plasmin inhibitor (alpha2-PI),fibrinogen (Fbg) and P-III-P in 44 consecutive adult patients undergoing allogeneic HSCT. Each parameter was determined before conditioning, on day 0 of HSCT and weekly for 5 weeks. Five of the 44 patients developed VOD at a median post HSCT of day 3 (range, day 3 to 12). On repeated analysis of variance (ANOVA), there were significant differences between patients with and without VOD in P-III-P (P < 0.0001), protein C (P < 0.0001), t-PA (P < 0.0001), PLG (P < 0.0001), AT-III(P < 0.0001), Fbg (P < 0.0001), alpha2-PI (P = 0.0002). Levels of P-III-P were significantly higher in patients with VOD than without VOD, before preparative chemotherapy (P < 0.005) and on days 0 and 7 (P < 0.001). On day 0, levels of t-PA were significantly higher in patients with VOD than without VOD (P < 0.05). On day 7, levels of protein C were significantly lower in patients with VOD than without VOD (P < 0.01). On day 0, there were trends of differences (P = 0.0515) between patients with and without VOD in the levels of protein C. These results suggest P-III-P, t-PA and protein C are predictive markers for VOD after HSCT in adults. Moreover, the serum P-III-P level before start of conditioning might indicate patients at risk for developing VOD.
肝静脉闭塞病(VOD)是造血干细胞移植(HSCT)后的一种主要并发症。其病因、诊断和治疗仍不明确。对HSCT后发生或未发生VOD的患者的凝血 - 纤溶参数和III型前胶原N端前肽(P-III-P)变化进行了研究。我们前瞻性地测定了44例连续接受异基因HSCT的成年患者的蛋白C活性、组织型纤溶酶原激活剂(t-PA)、抗凝血酶III(AT-III)、纤溶酶原活性(PLG)、凝血酶 - 抗凝血酶III复合物(TAT)、α2 - 纤溶酶抑制剂(α2-PI)、纤维蛋白原(Fbg)和P-III-P。在预处理前、HSCT第0天以及之后5周每周测定每个参数。44例患者中有5例在HSCT后第3天(范围为第3至12天)发生VOD。重复方差分析(ANOVA)显示,发生和未发生VOD的患者在P-III-P(P < 0.0001)、蛋白C(P < 0.0001)、t-PA(P < 0.0001)、PLG(P < 0.0001)、AT-III(P < 0.0001)、Fbg(P < 0.0001)、α2-PI(P = 0.0002)方面存在显著差异。VOD患者的P-III-P水平在预处理化疗前(P < 0.005)以及第0天和第7天(P < 0.001)显著高于未发生VOD的患者。在第0天,VOD患者的t-PA水平显著高于未发生VOD的患者(P < 0.05)。在第7天,VOD患者的蛋白C水平显著低于未发生VOD的患者(P < 0.01)。在第0天,发生和未发生VOD的患者在蛋白C水平上存在差异趋势(P = 0.0515)。这些结果表明,P-III-P、t-PA和蛋白C是成人HSCT后VOD的预测标志物。此外,预处理开始前的血清P-III-P水平可能表明患者有发生VOD的风险。